Procedural Outcomes of a Self-Expanding Transcatheter Heart Valve in Patients with Porcelain Aorta.

BACKGROUND

Severe calcification of the ascending aorta increases the peri-operative risk for neurological complications in patients with severe aortic stenosis. Transcatheter aortic valve implantation (TAVI) seems to be an optimal treatment option in these patients. However, the impact of the extent of aortic calcification on procedural and neurological outcomes during TAVI is unclear.

METHODS

Data from 3010 patients with severe native aortic valve stenosis treated with ACURATE from May 2012 to July 2022 were evaluated and matched by 2-to-1 nearest-neighbor matching to identify one patient with porcelain aorta (PA) ( = 492) compared with two patients without PA ( = 984). PA was additionally subdivided into circumferential (classic PA) ( = 89; 3.0%) and non-circumferential (partial PA) ( = 403; 13.4%) calcification. We compared outcomes according to VARC-3 criteria among patients with and without PA and identified predictors for occurrence of stroke in the overall population.

RESULTS

Technical success (88.5% vs. 87.4%, = 0.589) and device success at 30 days (82.3% vs. 81.5%, = 0.755) after transcatheter ACURATE implantation according to VARC-3 definition was high and did not differ between non-calcified aortas or PA. The rate of in-hospital complications according to VARC-3-definitions was low in both groups. Rates of all stroke (3.2% ( = 31) vs. 2.6% ( = 13), = 0.705) or transitory ischemic attacks (1.1% vs. 1.2%, = 1.000) did not differ significantly. Thirty-day all-cause mortality did not differ (3.0% vs. 3.2%, RR 1.1; = 0.775). Overall device migration/embolization (OR 5.0 [2.10;11.87]), severe bleeding (OR 1.79 [1.11;2.89]), and major structural cardiac complications (OR 3.37 [1.32;8.57]) were identified as independent predictors for in-hospital stroke in a multivariate analysis after implantation of ACURATE .

CONCLUSION

A porcelain aorta does not increase the risk of neurological complications after transfemoral ACURATE implantation. Based on these findings, transfemoral ACURATE implantation is safe in these particularly vulnerable patients.